InvestorsHub Logo
Followers 3
Posts 1036
Boards Moderated 0
Alias Born 02/07/2016

Re: None

Friday, 06/21/2024 4:54:53 PM

Friday, June 21, 2024 4:54:53 PM

Post# of 9353
argenx Announces FDA Approval of VYVGART
Hytrulo for Chronic Inflammatory Demyelinating
Polyneuropathy
4:50 PM ET 06/21/2024 | GlobeNewswire
ARGX
argenx Announces FDA Approval of VYVGART
Hytrulo for Chronic Inflammatory Demyelinating
Polyneuropathy
VYVGART(R) Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
First novel, precision mechanism of action in more than 30 years for patients with CIDP
Third approved indication for VYVGART(R) and
VYVGART Hytrulo franchise
Management to host conference call on June 21, 2024 at 11:00pm CET (5:00pm ET)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News